The top medtech stories of early 2017

The new Trump administration and Republican Congress – and all the accompanying change and uncertainty –is the major story for the medical device industry. But there are many other medtech stories worth noting from the first quarter of 2017. There was an FDA warning over Abbott’s Absorb bioresorbable stent, a continued spate of M&A deals, a

Pages: 1 2 3 4 5 6

FDA: St. Jude Medical devices really do have a cybersecurity problem

FDA issued a safety communication on January 9, 2017, detailing St. Jude Medical products that could be vulnerable to cyber threats. These threats could result in rapid battery depletion or administration of inappropriate pacing or shocks—potentially lethal outcomes. FDA noted that there have been no reports of patient harm related to the cybersecurity risks. The news comes

St Jude releases FDA-cleared Merlin@home cybersecurity update

Abbott (NYSE:ABT) subsidiary St. Jude Medical said it launched a cybersecurity update for its Merlin@home remote monitoring system designed for use with implantable pacemakers and defibrillator devices. The Little Canada, Minn.-based company said the move was made to “complement the company’s existing measures and further reduce the extremely low cybersecurity risks.” Read the full story at

St. Jude Medical learns hard digital lessons with CardioMEMS

As a device part of what some call the healthcare revolution, CardioMEMs HF from St. Jude Medical ticks all the boxes. It is the first permanent diagnostic cardiovascular implant, and a big deal in terms of developing the digital healthcare market. The device enables mobile monitoring of patients at risk for heart failure. It works